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The Behavioral Risk Factor Surveillance System (BRFSS) survey is used to estimate chronic 
obstructive pulmonary disease (COPD) prevalence and could be expanded to describe respiratory 
symptoms in the general population and to characterize persons with or at high risk for the disease. 
Tobacco duration and respiratory symptom questions were added to the 2012 South Carolina 
BRFSS. Data concerning sociodemographics, chronic illnesses, health behaviors, and respiratory 
symptoms were collected in 9438 adults ≥ 35 years-old. Respondents were categorized as having 
COPD, high risk, or low risk for the disease. High risk was defined as no self-reported COPD, ≥ 
10 years’ tobacco use, and ≥ 1 respiratory symptom (frequent productive cough or shortness of 
breath (SOB), or breathing problems affecting activities). Prevalence of self-reported and high-risk 
COPD were 9.1% and 8.0%, respectively. Overall, 17.3%, 10.6%, and 5.2% of all respondents 
reported activities limited by breathing problems, frequent productive cough, and frequent SOB, 
respectively. The high-risk group was more likely than the COPD group to report a productive 
cough and breathing problems limiting activities as well as being current smokers, male, and 
African-American. Health impairment was more severe in the COPD than the high-risk group, and 
both were worse than the low-risk group.
Conclusions—Persons at high risk for COPD share many, but not all, of the characteristics of 
persons diagnosed with the disease. Additional questions addressing smoking duration and 
respiratory symptoms in the BRFSS identifies groups at high risk for having or developing COPD 
who may benefit from smoking cessation and case-finding interventions.
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Introduction
Chronic obstructive pulmonary disease (COPD) may be the most preventable major cause of 
death from chronic disease in the United States, as it has one of the highest rates of 
smoking-attributable mortality (1). Although chronic lower respiratory disease (> 95% 
COPD) is the third-leading cause of mortality in the United States (2), the burden of COPD 
is even more substantial as a co-morbidity in other common causes of deaths (3, 4). Clearly, 
more extensive efforts are needed not only for primary prevention, but also for secondary 
prevention through greater recognition of undiagnosed disease. It has been reported that 
there are as many or more persons with undiagnosed COPD as are diagnosed with the 
disease (5–7). Strategies to help target undiagnosed patients include the use of risk-defining 
questionnaires (7–11) and spirometry for case-identification among persons at risk for 
COPD (12, 13).
Surveillance studies used to estimate the prevalence and impact of COPD in the United 
States include the National Health and Nutrition Examination Survey (NHANES) (5), 
National Health Interview Survey (NHIS) (14), and more recently the Behavioral Risk 
Factor Surveillance System (BRFSS) (14–16). The BRFSS is an annual, state-based, 
telephone health survey that collects data on sociodemographics as well as many of the 
behaviors and conditions that place adults at risk for chronic disease, typically greater than 
10,000 respondents in each state, and collectively in almost one-half million nationally. In 
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2007, a COPD prevalence question and a COPD impact module were added to one state’s 
(North Carolina’s) BRFSS (15). The prevalence question used in North Carolina was 
subsequently introduced in all states’ BRFSS in 2011, with numerous states also 
incorporating the optional COPD impact module (16).
In 2012, we added an additional COPD module to the South Carolina (SC) BRFSS, termed 
the COPD at-risk module, which included questions about respiratory symptoms and 
duration of tobacco use. Through the addition of the COPD at-risk module with other 
COPD-related questions previously incorporated in the BRFSS, we hypothesized that the 
survey could be a valuable tool to describe respiratory symptoms in the general adult 
population, health-related characteristics of persons with undiagnosed or at significant risk 
for developing COPD as well as those with self-reported provider-diagnosed COPD.
Methods
Study population and survey
The BRFSS, a random digit-dialed telephone survey of non-institutionalized adults (≥18 
years), is conducted annually with assistance from the Centers for Disease Control and 
Prevention (CDC) by state health departments as well as the District of Columbia and U.S. 
territories. In 2012, the South Carolina Department of Health and Environmental Control 
and North Carolina COPD Taskforce collaborated to include the COPD at-risk questions as 
a supplementary module (COPD at-risk module). The module was primarily intended to 
identify respondents at high risk of having or developing COPD and consisted of 4 
additional questions: 3 regarding respiratory symptoms and 1 to define lifetime smoking 
duration. A secondary objective was to describe respiratory symptoms in a state’s general 
adult population. The at-risk questions were derived from previously published COPD 
screening questionnaires (8–11).
The survey was administered by the University of South Carolina Institute for Public 
Service and Policy Research to 12,795 SC adults (9208 landline and 2606 cellular telephone 
respondents completed the survey, and 620 landline and 361 cellular telephone respondents 
partially completed the survey). Response rates for BRFSS were calculated using the 
American Association of Public Opinion Research Response Rate Formula #4 standards. 
(http://www.aapor.org/Standard_Definitions2.htm). The response rate for SC in 2012 was 
higher than the national median rate (48.6% vs 45.2%) (17). Due to the low prevalence and 
risk for COPD in younger adults, we limited our analyses to adults aged ≥ 35 years (n = 
10,863). Respondents were excluded if they were missing data on COPD (n = 3), smoking 
status (n = 218), smoking duration (n = 584), or one or more respiratory symptoms (n = 
1085) (total excluded = 1425). The final sample size for data analysis included 9438 adults 
(87% of respondents ≥ 35 years). Beginning in 2011, a new weighting methodology (raking, 
also known as iterative proportional fitting) replaced post-stratification for calculation of 
sample weights. BRFSS uses 8 demographic variables (age group by gender, race/ethnicity, 
education, marital status, tenure, gender by race/ethnicity, age group by race/ethnicity, and 
phone ownership) in the raking procedure. Raking adjusts for non-coverage and non-
response (18). The BRFSS has been approved as exempt research by the CDC’s institutional 
review board.
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Respiratory symptoms in the at-risk module
Respondents were asked, “How often do you cough up mucus or phlegm?” Frequent 
productive cough was defined as either most days a week or every day. Respondents were 
also asked, “During the past 30 days, how often did you feel short of breath?” Frequent 
shortness of breath (SOB) was defined as most of the time or all of the time. Finally, 
respondents were asked, “Thinking about your physical activity during the last 12 months, 
do you agree slightly or strongly or disagree slightly or strongly with the following 
statement—I do less now than I used to because of my breathing problems.” Respondents 
who agreed strongly or slightly were characterized as agreeing that breathing problems 
limited their physical activity. These questions were derived from prior COPD screening 
questionnaires (8–10).
Tobacco use and duration
All respondents were asked, “Have you smoked at least 100 cigarettes in your entire life?” 
Persons with a negative response were categorized as never smokers. Persons with an 
affirmative response were further asked, “Do you now smoke cigarettes every day, some 
days, or not at all?” to define current and former smokers. Current and former smokers were 
asked, “Over your lifetime, how many years have you smoked tobacco products?”
Prevalence and risk of COPD
All respondents were asked, “Has a doctor, nurse, or other health professional ever told you 
that you had chronic obstructive pulmonary disease or COPD, emphysema, or chronic 
bronchitis?” Persons with self-reported COPD were also asked whether they had ever 
undertaken a diagnostic breathing test and if SOB affected their quality of life. Three COPD 
risk categories were defined based upon prior diagnosis, respiratory symptoms, and tobacco 
use duration: 1) Diagnosed COPD: self-report of provider-diagnosed COPD; 2) High-risk: 
respondents with no COPD diagnosis, ≥ 10 years of tobacco product use, and ≥ 1 respiratory 
symptom (frequent productive cough, frequent SOB, or decreased physical activity due to 
breathing problems); and 3) Low-risk: neither diagnosed with COPD nor at high risk. In 
addition to sociodemographic variables, all respondents were also asked about their access 
to health care, chronic conditions, and overall health status.
Statistical analysis
All analyses were conducted using SAS-callable SUDAAN (version 11.0.0, RTI 
International, Research Triangle Park, NC) to account for the complex sampling design. 
First, we calculated the prevalence and 95% confidence intervals (CI) of respiratory 
symptoms and COPD by selected characteristics. For comparisons of prevalence between 
subgroups, statistical significance was determined using t-tests. We also tested for linear 
trends across age and smoking duration categories using the Wald F-statistic. Age-adjusted 
prevalence and 95% CI of selected characteristics by COPD risk status were then calculated. 
Prevalences were compared by risk status using pairwise t-tests. A p-value <0.05 was 
considered statistically significant for all tests.
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Among 9438 adults aged ≥35 years, 9.1% were diagnosed with COPD, 8.0% were high risk 
for COPD, 10.6% reported frequent productive cough, 5.2% reported frequent SOB, and 
17.3% agreed that physical activity was limited over the past 12 months due to breathing 
problems. In persons with COPD, 82.0% (78.4–85.3) reported having a diagnostic breathing 
test, 70% (65.2–74.3) reported SOB affected their quality of life. Table 1 shows the 
prevalence of each respiratory symptom, if frequent, and COPD for groups defined by 
selected characteristics. The prevalence of respiratory symptoms did not differ significantly 
by gender; however, diagnosed COPD was more common among women than men (9.9% 
vs. 8.1%, p = 0.03). The prevalence of all respiratory symptoms and COPD increased with 
age (linear trend p < 0.001 for frequent productive cough, breathing problems limited 
physical activity, and COPD; p = 0.009 for frequent SOB). Compared to Whites, African-
Americans were more likely to report frequent SOB and that breathing problems limited 
physical activity, but less likely to report being diagnosed with COPD. Those who were 
unable to work reported the highest prevalence of each respiratory symptom and COPD. 
Among those who were unable to work, half agreed that breathing problems limited their 
physical activity and more than a quarter had COPD. There was a higher prevalence of 
respiratory symptoms and COPD among individuals in lower education groups. Frequent 
respiratory symptoms and COPD were more common among current smokers than former 
smokers and among former smokers than never smokers (p < 0.01). The prevalence of each 
respiratory symptom and COPD also increased with years of smoking duration (linear trend 
p < 0.0001 for all).
Table 2 shows characteristics of SC adults aged ≥ 35 years among the three risk categories. 
Compared with adults diagnosed with COPD, those at high risk were more likely to be male, 
African-American, and current smokers and less likely to be female, or unable to work. 
Combined, nearly 60% of persons at high-risk were in the 45–54 and 55–64-year-old age 
groups. Prevalence of various health-related characteristics and respiratory symptoms were 
also assessed by COPD risk status (Table 3). Compared with adults diagnosed with COPD, 
those at high risk were more likely to report fewer chronic conditions including asthma, 
arthritis, cancer, and depression; frequent productive cough; and that breathing problems 
limited physical activities.
Health impairment measures such as frequent physical distress were less prevalent in the 
high-risk than the COPD group, and both groups were substantially worse than the low-risk 
group. The Venn diagrams in Figure 1 show the relationships of the prevalence for each 
symptom (frequent only) and overlap for the COPD and high-risk groups. Persons with 
COPD were three-fold more likely to report all three symptoms than those at high-risk. One-
third of persons with COPD did not report frequent productive cough, frequent SOB, nor 
significant effects of breathing problems on physical activities.
Discussion
We undertook the first use of the BRFSS to assess respiratory symptoms in the adult 
population, primarily to describe individuals at high risk for COPD as well as those with 
Pleasants et al. Page 5













COPD. Among all subjects, the most frequent respiratory symptom reported was physical 
activities limited by breathing problems. Respiratory symptoms were uncommon in persons 
who smoked less than 10 years and did not self-report COPD (low-risk group). Among all 
survey participants, we found 1 in 6 adults aged ≥35 years in SC reported COPD or were at 
high risk of having or developing the disease based upon respiratory symptoms, age, and 
tobacco history; furthermore, there were nearly as many adults in the high-risk as in the 
COPD group.
The high-risk group likely includes those with undiagnosed COPD or at significant risk of 
ultimately developing the disease. The high-risk and COPD groups shared many 
sociodemographic and health characteristics, however some measures differed. One key 
difference was gender; in contrast to those with diagnosed COPD where the percentage of 
females was greater, males were more likely to be at high risk than females. In addition, 
African-Americans were also more likely to be at high risk for COPD.
Low socioeconomic status was evident in both the high-risk and COPD groups. Healthcare 
access was similar between these two groups, suggesting the need for better case-finding 
efforts in clinical settings and ready availability of spirometry. The inclusion of COPD 
screening questions in the BRFSS could be used to describe persons for whom population-
based and case-finding efforts for COPD might be undertaken at local and state levels. 
Further, this approach helps better define respiratory symptoms in a general adult population 
for which there is a paucity of data in the United States.
There are few published studies concerning respiratory symptoms, particularly SOB, in 
adults at risk for or with COPD in a general adult population (5, 19). In our study, frequent 
productive cough was reported in ~10% of all respondents, one-third of those with COPD, 
and one-half of the high-risk group. In a study using 2007–2010 NHANES data, frequent 
phlegm or cough were reported in 7.4% and 10.8% of all subjects (n = 5139), 9.1% and 
9.3% of those with mild airflow obstruction, and 19.8% and 24.2% in moderate to severe 
airflow obstruction, respectively (19). In our study, the more frequent productive cough in 
high-risk persons compared to diagnosed COPD and the low-risk group may be related to 
differences in current smoking rates. Respiratory symptoms, particularly productive cough, 
are common in smokers, especially in those with diagnosed (20) or undiagnosed COPD (21).
Similar to our results, a large international study reported 34.6% of COPD patients had 
chronic bronchitis (defined as “phlegm on most days for 3 or more consecutive months 
during the year and trouble with phlegm for 2 or more years”) (22). Our findings also agree 
with a study in which COPD patients with chronic bronchitis were younger and more likely 
to be current smokers compared with those without (23). Chronic bronchitis is associated 
with poor quality of life, more exacerbations (19, 24) and greater mortality (25). Dyspnea 
has been reported in 30–50% of persons with undiagnosed airflow obstruction (6, 26). 
Frequent dyspnea, seen in a higher portion of COPD than high-risk persons in this study, is 
likely reflective of more advanced disease, increasing the probability of diagnosis (26). 
Hanania et al. reported that a combination of both dyspnea and cough are predictive of 
airflow obstruction in COPD patients (10). We found that the minority of persons in both the 
COPD and high-risk groups reported two or more frequent respiratory symptoms (Figure 1). 
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People with frequent productive cough and limitation of activities due to breathing 
problems, but not frequent SOB, may represent earlier stages of COPD.
A diagnosis of COPD is reported in 6–7% of U.S. adults (5, 16). We found the age-adjusted 
prevalence of self-reported COPD in SC to be 9.1%, among whom more than 80% indicated 
they had had a diagnostic breathing test, presumably spirometry. Prior studies have reported 
the relationship between self-reported, provider-diagnosed COPD and spirometrically 
confirmed disease (27, 28). One study of a cohort of nurses has shown a good correlation 
between self-reported and spirometry-confirmed COPD (78% sensitivity) (27). In a 
NHANES study of a representative sample of the U.S. adult population, > 95% of persons 
with self-reported, provider-diagnosed chronic bronchitis or emphysema had evidence of 
mild or moderate airflow obstruction by spirometry (28).
Among a sample of the Swedish general population, self-reported physician diagnosis of 
COPD had high specificity (99%) and good positive predictive value for airflow obstruction 
assessed by spirometry, but low sensitivity, which could result in underestimated prevalence 
in the general population (29). Based on the at-risk module, without spirometry, we found 
the prevalence of high risk for COPD to be almost as high as that of diagnosed COPD. The 
NHANES health surveys have reported that there are more persons with airflow obstruction 
based upon spirometry than those known to have asthma or COPD (5, 29). Whether based 
on population screening including spirometry as done in NHANES or using a symptom and 
exposure-based questionnaire like the current study, the number of probable undiagnosed 
COPD patients is substantial.
Similar to studies that compared diagnosed to undiagnosed COPD patients (6, 7) the COPD 
and high-risk groups in our study shared many characteristics. Prolonged smoking, greater 
than 20 years, was common in both the high-risk and COPD groups. Like other studies, we 
found that low socioeconomic status is common in both diagnosed (30) and high-risk 
persons, likely related to higher smoking rates (7, 31), and that females were more prevalent 
in the diagnosed COPD group (5). Our data in the high-risk group agrees with a study of 
undiagnosed COPD where males were more prevalent (6); however, the same study also 
found a higher prevalence of diagnosed COPD among men. Our observation concerning 
African-Americans is a new finding. Although tobacco use rates are similar between whites 
and African Americans (1), COPD-related mortality is most evident in the former group (14, 
32). Our data suggest this may be partially related to under-recognition. As most COPD 
patients are managed in the primary care setting (33), general practitioners should be able to 
recognize characteristics of high-risk patients to assist in case-finding efforts.
COPD is a complex respiratory disease associated with systemic manifestations and co-
morbidities including asthma, heart disease, musculoskeletal disease, depression, and cancer 
(34–37). Little has been published about the type or prevalence of co-morbidities in 
undiagnosed COPD (38). We found that some co-morbidities were more common in the 
COPD group than either the high-risk or low-risk groups, particularly asthma, cancer, and 
depression. Coronary heart disease, diabetes mellitus, stroke, and kidney disease occurred at 
similar frequencies between the COPD and high-risk groups. Multiple (> 3) co-morbidities 
were more common in both the COPD and high-risk groups compared to the low-risk group. 
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The increased risk of co-morbidities in the high-risk group compared to the low-risk group 
is important considering the significant impact on health status, healthcare utilization, 
hospitalization, and mortality in COPD (34, 35).
Our approach to identify at-risk persons based on age, tobacco use, and respiratory 
symptoms is consistent with COPD guidelines that recommend case-finding in symptomatic 
persons with an exposure history, but discourage population screening in asymptomatic 
persons (39, 40). It has been shown that the majority of asymptomatic persons with airflow 
obstruction have mild disease (7, 33), and there is little evidence that diagnosing 
asymptomatic smokers leads to better outcomes (40). However, health impairment is often 
present in people with undiagnosed COPD (6, 7), and spirometry may increase smoking 
cessation effectiveness (41). We also observed significant health impairment in the high-risk 
group, although the contribution of respiratory symptoms versus other etiologies is unclear.
When using respiratory symptoms and/or smoking history to identify undiagnosed COPD 
patients in primary care settings, 13–27% of those at-risk were spirometrically diagnosed 
(10,13,22,42,43). Patient care settings such as indigent clinics with higher smoking 
frequencies may yield higher rates of COPD diagnosis. The validity of using a symptom-
based method to screen for COPD is supported by studies showing dyspnea (44), chronic 
bronchitis (45), or a modified BODE score (46) (multiple measures including dyspnea) were 
a stronger predictor than FEV 1 alone for mortality in COPD.
Our study had several limitations. Responses were obtained by telephone survey; therefore 
we relied on self-report of symptoms, medical conditions, and smoking history. Reports of 
COPD diagnoses were not confirmed with spirometry or review of medical records, which 
could result in misclassification of respondents. However, the validity of COPD by self-
report in the SC BRFSS respondents is supported by:
82% reported a prior diagnostic breathing test; 70% indicated SOB affected their quality of 
life; Disease prevalence is similar to another U.S survey, National Health Information 
Survey, for the East South Central states (9.1% vs 7.5%) (47); Frequency of current tobacco 
use and co-morbidities including asthma and diabetes mellitus in the current study were 
similar to a study conducted in the southeastern Kentucky adult population (48); and, Two 
prior studies report that > 95% of persons with a self-report of provider-diagnosed COPD 
have airflow obstruction, when confirmatory spirometry was performed (28, 29).
Although pack-years (product of intensity and duration) is the most frequent clinical 
measure for tobacco exposure, we used smoking duration, as two survey questions would 
have been required otherwise.
A study comparing the effects of smoking status, duration, and intensity on lung cancer risk 
reported current smoking and intensity were the best predictors of risk, however duration 
was only slightly less predictive (49). In addition, a recent study assessing tobacco-related 
mortality over 50 years showed that smoking duration and intensity were both associated 
with increased COPD mortality (50). We did not include persons with no or <10 years of 
smoking with frequent symptoms as part of the high-risk group, thus missing a potentially 
important group since a quarter of patients with COPD are never-smokers (51). The addition 
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of cellular telephones to target respondents began in 2011 and the BRFSS survey response 
rates have decreased to less than 50%. Inclusion of these households has improved coverage 
of respondents with lower income or education levels, as well as younger respondents (52). 
Finally, this survey was performed in one state and additional studies will be undertaken in 
2015 to determine the external validity and generalizability of these findings.
Conclusions
By using a questionnaire incorporated into the BRFSS to estimate the frequency of cough, 
SOB, physical impairment associated with breathing problems, and years of tobacco use, we 
were able to describe respiratory symptoms in a general adult population, better characterize 
persons with COPD, and to also identify a target population at high risk for having or 
developing COPD. We found there were many similarities between persons who reported a 
provider-diagnosis of COPD and those who were at high risk. However, males and African-
Americans appear to be at greater risk for having undiagnosed COPD than their 
comparators. Our surveillance approach addresses several goals stated in the USA CDC’s 
Public Health Strategic Framework for COPD Prevention (53) and could provide a forum 
for advocacy, policy change, and for influencing clinical practice at local and state levels. 
An approach that combines public health (prevention, surveillance) and healthcare (case 
finding, guideline-based care) strategies can potentially have a significant impact on COPD, 
the most preventable cause of death from a chronic disease in the United States.
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